
    
      This is a randomized, double-blind, placebo-controlled study to assess the efficacy and
      safety of NYX-2925 in subjects with fibromyalgia.

      This 13- to 16-week study will include a 1- to 4-week Screening Period followed by a 12-week
      double-blind, randomized, placebo-controlled Treatment Period.
    
  